

Dynamic Synergy

Mitsubishi Tanabe Pharma Corporation
ANNUAL REPORT 2010



Mitsubishi Tanabe Pharma

OUR PHILOSOPHY

We contribute to the healthier lives of people around the world through the creation of pharmaceuticals.

OUR VISION

We strive to be a global research-driven pharmaceutical company that is trusted by communities.

Mitsubishi Tanabe Pharma Corporation was established in October 2007 through the merger of Tanabe Seiyaku Co., Ltd., and Mitsubishi Pharma Corporation. Our vision is to be a global research-driven pharmaceutical company that is trusted by communities.

We will strive to make rapid progress toward being a company that can continually provide new pharmaceuticals to patients around the world. In this way, we will contribute to the healthier lives of those patients and fulfill our responsibilities as a company engaged in the life sciences.

We provide distinctive pharmaceuticals that meet a wide range of medical needs.

Mitsubishi Tanabe Pharma has a wide-ranging product lineup that meets diverse medical needs. One feature of the Company's operations is that it sells distinctive drugs, including drugs for autoimmune diseases, cerebral diseases, and circulatory problems as well as psychiatric and neurological drugs, narcotics, fractionation products, vaccines, and OTC drugs. Remicade, one of the Company's core products, is a groundbreaking biological agent with indications for a number of autoimmune diseases, including rheumatoid arthritis (RA). Remicade has earned strong evaluations in clinical settings, and sales in fiscal 2009, ended March 31, 2010, were ¥47.2 billion.



FORWARD-LOOKING STATEMENTS

Statements contained in this annual report that are not historical facts are forward-looking statements that reflect the Company's plans and expectations. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company's actual results, performance, or achievements to differ materially from those anticipated in these statements.

We have a strong presence in the domestic market for ethical drugs.

Mitsubishi Tanabe Pharma's marketing capabilities place the Company in the top ranks of pharmaceutical companies in Japan, and in fiscal 2009 the Company was ranked fifth in domestic sales of ethical drugs. Moving forward, to achieve our vision of being a global research-driven pharmaceutical company, we must bolster our domestic operational foundation, which will support new drug development and overseas business expansion. Profits earned through domestic operations will be the driving force behind the realization of our vision, and accordingly we are taking steps to further enhance our presence in the domestic market.

We are making steady progress in establishing a robust R&D pipeline.

Aiming to be a pharmaceutical company that can continually provide new drugs to patients around the world, Mitsubishi Tanabe Pharma is working to strengthen its R&D pipeline. The Company has positioned the metabolism and circulation disease areas as key areas in R&D. Centered on these areas and on autoimmune diseases, promising late-stage development projects are making steady progress. Mitsubishi Tanabe Pharma's R&D pipeline includes many projects in phase 3 or phase 2/3 and projects for which New Drug Applications (NDAs) had been filed (including licensed products).



CONTENTS	Management Strategies	2	Overview of Core Ethical Drugs and Sales Trends	24
	Financial Highlights	4	Corporate Governance and Internal Control	26
	Message from the President	5	Corporate Social Responsibility	30
	Research and Development	14	Board of Directors and Auditors	32
	Close Up:		Financial Section	33
	Targeting the Discovery of New Growth Drivers	16	Group Companies	72
	State of New Product Development	18	Corporate Data / Investor Information	73
	Marketing Activities	20		
	Close Up:			
	Aiming to Further Increase the Product Value of Remicade	22		